ESTRO 2025 - Abstract Book

S2255

Interdisciplinary – Global health

ESTRO 2025

Keywords: CT-scan, PET-CT, staging

4635

Digital Poster Sexual dysfunction and quality of life in prostate cancer patients treated with radiotherapy. Analysis in Mexican population. David Hernandez-Martinez 1 , Regina del Carmen Landa-Garcia 2 , Celia Beatriz Gonzalez-Alcorta 1 , Camila Alejandra Martinez-Roque 3 , Itzel Lidey Galaviz-Reynoso 3 , Eloise Emma Raymonde-Ferlay 3 , Paola Azucena Lopez-Sierra 3 , Rafael Piñeiro-Retif 4 , Oscar Vidal-Gutierrez 4 , Juan Francisco Gonzalez-Guerrero 4 , Adelina Alcorta-Garza 3 1 Radiation Oncology, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico. 2 Internal Medicine, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico. 3 Psycho-Oncology, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico. 4 Oncology, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico Purpose/Objective: Prostate cancer diagnosis adversely affects sexual function, often due to psychological distress. Oncological treatments like surgery, radiotherapy, or androgen deprivation therapy further worsen sexual function, reported by 80% of patients. These treatments also cause psychosocial impacts that reduce quality of life (QoL). In Mexico, there is limited data on this topic. This study assessed sexual dysfunction and QoL in prostate cancer patients treated with radiotherapy, exploring correlations between sexual function and QoL related to sexual interest, active sexual life, and male sexuality. Material/Methods: A cross-sectional study was conducted from July to October 2024 at the Oncology Department of the “Dr. José Eleuterio González” University Hospital with 70 outpatient prostate cancer patients receiving radiotherapy. Erectile function was assessed using the IIEF-5 scale. QoL was evaluated with: 1.Generic EORTC QLQ-C30: Focused on physical, emotional, cognitive, and social well-being (scores 0-100; higher scores indicate better QoL). 2.Prostate-specific EORTC QLQ-PR25: Assessed sexual interest, activity, and symptom severity (urinary, intestinal, hormone therapy-related). 3.Male sexuality-specific SQOL-M: Measured male sexual QoL (scores 0-100; higher scores indicate better QoL). Spearman correlation coefficients were calculated to explore relationships between sexual function and QoL indicators, adjusted for age. Results: Participants (mean age: 69.8 ± 6.8) largely reported low confidence in achieving/maintaining erections and difficulty sustaining them during penetration. Generic QoL had a high mean score (97.9 ± 3.9), while QoL related to sexual interest and activity scored lower (37.0 ± 14.5). Urinary symptoms (33.9 ± 9.7) were the most severe, followed by intestinal (26.4 ± 6.2) and hormone therapy-related symptoms (28.3 ± 4.8). QoL linked to male sexuality was high (98.5 ± 5.5). Positive correlations were observed between sexual function and QoL related to sexual interest and activity (rho = 0.624 and 0.572; p < 0.001), but not with male sexuality or generic QoL. Conclusion: Sexual dysfunction significantly impacts QoL related to sexual interest and activity in prostate cancer patients treated with radiotherapy, though it does not affect overall generic QoL. However, this underscores the importance of a multidisciplinary approach and the implementation of enhanced preventive measures.